Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study

Table 4

Clinical and virological characteristics of chronic hepatitis C patients with DAAs treatment.

Patients’ characteristics	n = 405
Female, n (%)	232 (57.14%)
Median age (IQR), years	56 (49, 63)
Median BMI (IQR), kg/m^2	24.17 (21.97, 26.30)
Cirrhosis, n (%)	164 (40.39%)
Compensated	107 (26.35%)
Decompensated	57 (14.04%)
HCC, n (%)	12 (2.96%)
Comorbidity, n (%)
Hypertension	59 (14.53%)
Type 2 diabetes	71 (17.49%)
Hematological system disease	3 (0.74%)
Median baseline HCV RNA (IQR), lg·IU/ml	6.23 (5.52, 6.71)
Noncirrhosis	6.24 (5.52, 6.76)
Compensated cirrhosis	6.26 (5.53, 6.62)
Decompensated cirrhosis	5.86 (5.12, 6.49)
Genotypes, n (%)
1b	321 (79.06%)
2a	74 (18.23%)
3a	3 (0.74%)
3b	3 (0.74%)
6a	5 (1.23%)
Treatment history, n (%)
Naive	379 (93.35%)
Experience	27 (6.65%)

HCV: hepatitis C virus; DAA: directing antiviral agents; BMI: body mass index; HCC: hepatocellular carcinoma; and IQR: interquartile range.